Ewa Sapiejka1, Patrycja Krzyżanowska-Jankowska2, Ewa Wenska-Chyży2, Mariusz Szczepanik2, Dariusz Walkowiak3, Szczepan Cofta4, Andrzej Pogorzelski5, Wojciech Skorupa6, Jarosław Walkowiak7. 1. The Specialist Centre for Medical Care of Mother and Child, Gdansk, Poland. 2. Department of Pediatric Gastroenterology and Metabolic Diseases, Poznan University of Medical Sciences, Poznan, Poland. 3. Department of Organization and Management in Health Care, Poznan, Poland. 4. University Hospital of Lord's Transfiguration, Partner of Poznan University of Medical Sciences, Poznan, Poland. 5. Department of Pulmonology and Cystic Fibrosis, Institute of Tuberculosis and Lung Diseases, Rabka-Zdroj, Poland. 6. Department of Lung Diseases, National Institute for Tuberculosis and Lung Diseases, Warsaw, Poland. 7. Department of Pediatric Gastroenterology and Metabolic Diseases, Poznan University of Medical Sciences, Poznan, Poland. Electronic address: jarwalk@ump.edu.pl.
Abstract
PURPOSE: The risk of vitamin E deficiency is of primary concern in cystic fibrosis patients. However, early diagnosis and routine vitamin E supplementation can lead to its normal or even high levels. In the present study, we assessed vitamin E status in a large group of cystic fibrosis patients. Moreover, we also aimed to establish determinants of its body resources in cystic fibrosis patients. MATERIAL AND METHODS: The study group comprised 211 cystic fibrosis patients aged from 1 month to 48 years. In all of them serum α-tocopherol concentration was analyzed using high-performance liquid chromatography. RESULTS: Median vitamin E concentration was 9.9 μg/ml (1st-3rd quartile: 7.5-13.5). Vitamin E deficiency was found in 17 (8.0%) and high levels were documented in 24 (11.4%) participants. Patients with and without vitamin E deficiency did not differ significantly with respect to age, standardized body weight and height, FEV1, albumin concentration and vitamin E supplementation dose. However, vitamin E deficiency appeared more frequently in participants without vitamin E supplementation. Moreover, in multiple linear regression analysis pancreatic insufficiency, severe CFTR gene mutation and vitamin E dose, were potentially defined as determinants of vitamin E concentration. CONCLUSIONS: Vitamin E deficiency in cystic fibrosis patients is rather rare nowadays. Excessive vitamin E levels seem to be more frequent. Vitamin E status wasn't documented to be strictly related to clinical determinants. Beyond vitamin E supplementation, exocrine pancreatic function and CFTR gene mutations may have had an impact on the vitamin E body resources in cystic fibrosis patients.
PURPOSE: The risk of vitamin E deficiency is of primary concern in cystic fibrosispatients. However, early diagnosis and routine vitamin E supplementation can lead to its normal or even high levels. In the present study, we assessed vitamin E status in a large group of cystic fibrosispatients. Moreover, we also aimed to establish determinants of its body resources in cystic fibrosispatients. MATERIAL AND METHODS: The study group comprised 211 cystic fibrosispatients aged from 1 month to 48 years. In all of them serum α-tocopherol concentration was analyzed using high-performance liquid chromatography. RESULTS: Median vitamin E concentration was 9.9 μg/ml (1st-3rd quartile: 7.5-13.5). Vitamin E deficiency was found in 17 (8.0%) and high levels were documented in 24 (11.4%) participants. Patients with and without vitamin E deficiency did not differ significantly with respect to age, standardized body weight and height, FEV1, albumin concentration and vitamin E supplementation dose. However, vitamin E deficiency appeared more frequently in participants without vitamin E supplementation. Moreover, in multiple linear regression analysis pancreatic insufficiency, severe CFTR gene mutation and vitamin E dose, were potentially defined as determinants of vitamin E concentration. CONCLUSIONS: Vitamin E deficiency in cystic fibrosispatients is rather rare nowadays. Excessive vitamin E levels seem to be more frequent. Vitamin E status wasn't documented to be strictly related to clinical determinants. Beyond vitamin E supplementation, exocrine pancreatic function and CFTR gene mutations may have had an impact on the vitamin E body resources in cystic fibrosispatients.
Authors: Jan K Nowak; Paulina Sobkowiak; Sławomira Drzymała-Czyż; Patrycja Krzyżanowska-Jankowska; Ewa Sapiejka; Wojciech Skorupa; Andrzej Pogorzelski; Agata Nowicka; Irena Wojsyk-Banaszak; Szymon Kurek; Barbara Zielińska-Psuja; Aleksandra Lisowska; Jarosław Walkowiak Journal: Nutrients Date: 2021-12-20 Impact factor: 5.717
Authors: Olaf Sommerburg; Susanne Hämmerling; S Philipp Schneider; Jürgen Okun; Claus-Dieter Langhans; Patricia Leutz-Schmidt; Mark O Wielpütz; Werner Siems; Simon Y Gräber; Marcus A Mall; Mirjam Stahl Journal: Antioxidants (Basel) Date: 2021-03-19
Authors: Jan Krzysztof Nowak; Patrycja Krzyżanowska-Jankowska; Sławomira Drzymała-Czyż; Joanna Goździk-Spychalska; Irena Wojsyk-Banaszak; Wojciech Skorupa; Ewa Sapiejka; Anna Miśkiewicz-Chotnicka; Jan Brylak; Barbara Zielińska-Psuja; Aleksandra Lisowska; Jarosław Walkowiak Journal: J Clin Med Date: 2022-01-17 Impact factor: 4.241